Topic

Toggle navigation

Turing Pharmaceuticals

This content is from: Portfolio

Drug Wars: The Battle to Put a Lid on Rising Prices

In the first of five stories on the battle to address skyrocketing drug prices in the U.S., Institutional Investor looks at how the actions of Turing Pharmaceuticals CEO Martin Shkreli set off a firestorm in Washington.
By Khadijah M. Silver
November 25, 2015
This content is from: Portfolio

Pharmaceutical Companies Gird for Drug-Price Reckoning

Uproar over suddenly hiked-up medications may not crush health care stocks for long, but it does force the industry to justify value.
By Kaitlin Ugolik
October 08, 2015
This content is from: Portfolio

Hedge Fund Manager Kyle Bass Declares War on Drug Prices

Through his Coalition for Affordable Drugs, Bass is challenging pharmaceuticals companies’ patents and shorting their stocks.
By Jess Delaney
October 22, 2015
This content is from: Portfolio

The Morning Brief: Marshall Wace Co-Founder Backs Controversial Plan
By Amanda Cantrell
September 24, 2015
This content is from: Portfolio

The Race to Rein in U.S. Drug Prices

The fifth and final story in our series on escalating U.S. drug prices looks at the impact that presidential politics will have on the pharma industry.
By Khadijah M. Silver
February 11, 2016
This content is from: Portfolio

Health Care Loans Offer Possible Remedy for High U.S. Drug Costs

MIT finance professor Andrew Lo thinks securitized loans could make livesaving therapies more accessible, but there are potential risks.
By Bailey McCann
March 18, 2016
See More Articles